Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

doi:10.1161/JAHA.115.002688

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.

Journal of the American Heart Association - 28 Mar 2016

Oemrawsingh Rohit M, Akkerhuis K Martijn, Van Vark Laura C, Redekop W Ken, Rudez Goran, Remme Willem J, Bertrand Michel E, Fox Kim M, Ferrari Roberto, Danser A H Jan, de Maat Moniek, Simoons Maarten L, Brugts Jasper J, Boersma Eric

Abstract excerpt

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate combined risk prediction model. METHODS AND RESULTS: Clinical, genetic, and outcomes data were used from 8726 stable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Decision Support Techniques

Share to Double-Blind Method

Share to Drug Costs

Share to Heart Arrest

Share to Patient Selection

Share to Receptor, Angiotensin, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 27021566
DOI: 10.1161/JAHA.115.002688
PMCID: PMC4943245

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.PMID 27021566Read ↗

Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.Semantic proximity Read ↗

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.Semantic proximity Read ↗

A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals.Semantic proximity Read ↗

Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.Semantic proximity Read ↗

Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.Semantic proximity Read ↗

A randomized trial of genotype-guided perindopril use.Semantic proximity Read ↗

Meta-Analysis of the Efficacy and Safety of Genotype-Guided Strategy for Selection of P2Y12 Inhibitors in Coronary Artery Disease.Semantic proximity Read ↗

Subgroups at high risk for ischaemic heart disease:identification and validation in 67 000 individuals from the general population.Semantic proximity Read ↗

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.Semantic proximity Read ↗

Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes.Semantic proximity Read ↗

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.Semantic proximity Read ↗

Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.